UCB SA (OTCMKTS:UCBJF) Sees Large Increase in Short Interest

UCB SA (OTCMKTS:UCBJF - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 584,000 shares, an increase of 21.4% from the March 15th total of 481,000 shares. Currently, 0.3% of the company's shares are sold short. Based on an average daily volume of 700 shares, the days-to-cover ratio is currently 834.3 days.

UCB Stock Performance

Shares of UCBJF stock remained flat at $150.70 on Thursday. The company's 50-day simple moving average is $178.59 and its 200-day simple moving average is $183.57. UCB has a twelve month low of $126.05 and a twelve month high of $209.66. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.